For patients, the immense value of a life-changing medication can be difficult to quantify. Yet as drug prices rise, more health insurers and policy analysts are trying to do just—create a price point based upon a medical therapy’s clinical effectiveness. But when market price doesn’t conform to analysts’ value assessment, effectiveness data can be used to justify limiting patients’ access to breakthrough treatments. Such could be the case with a new study from the Institute for Clinical and Economic Review, which considers the value two new drugs for treating high cholesterol.
More at Institute for Patient Access